Pharvaris (NASDAQ:PHVS) Coverage Initiated at Wolfe Research

Equities research analysts at Wolfe Research initiated coverage on shares of Pharvaris (NASDAQ:PHVS) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $42.00 price target on the stock. Wolfe Research’s price target would indicate a potential upside of 57.72% from the company’s previous close.

PHVS has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Royal Bank Of Canada reduced their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Sunday, April 5th. Finally, Wedbush increased their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.73.

Pharvaris Price Performance

Shares of PHVS stock opened at $26.63 on Thursday. The firm has a 50-day moving average of $27.05 and a 200-day moving average of $25.52. The company has a market cap of $1.74 billion, a P/E ratio of -7.90 and a beta of -2.58. Pharvaris has a one year low of $11.66 and a one year high of $29.85.

Insiders Place Their Bets

In related news, CEO Berndt Modig sold 23,333 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42. Following the completion of the transaction, the chief executive officer owned 142,084 shares in the company, valued at approximately $3,941,410.16. This represents a 14.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 11.84% of the company’s stock.

Hedge Funds Weigh In On Pharvaris

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in Pharvaris during the fourth quarter worth about $35,000. Barclays PLC bought a new position in Pharvaris during the fourth quarter worth about $77,000. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris during the third quarter worth about $75,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Pharvaris during the fourth quarter worth about $86,000. Finally, JPMorgan Chase & Co. boosted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $42 price target (~58% upside vs. current levels), which can boost investor interest and buying pressure. Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation
• Positive Sentiment: Wedbush raised its price target on PHVS to $42, aligning with other bullish voices and reinforcing the street’s constructive view on Pharvaris’ growth/valuation runway. Wedbush Increases Pharvaris (NASDAQ:PHVS) Price Target to $42.00
• Neutral Sentiment: HC Wainwright published earnings/long‑term model commentary for Pharvaris (estimating FY2030 figures and Q1 outlook). Analyst model updates can influence expectations but are not an immediate catalyst absent new clinical or commercial data. HC Wainwright Predicts Pharvaris FY2030 Earnings
• Neutral Sentiment: Reported short-interest data is effectively zero (no measurable short volume), so short-covering or squeeze dynamics are unlikely to be a driver in the near term. (Internal reporting entry.)
• Negative Sentiment: CEO Berndt Modig sold 23,333 shares (~14.1% reduction in his reported position) under a pre-arranged Rule 10b5-1 plan for proceeds ~ $647k. Insider sales can be interpreted negatively by some investors even when executed under 10b5-1 plans. SEC filing for insider sale

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.